{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,13]],"date-time":"2025-12-13T06:27:52Z","timestamp":1765607272749,"version":"3.48.0"},"reference-count":32,"publisher":"BMJ","issue":"3","license":[{"start":{"date-parts":[[2022,3,25]],"date-time":"2022-03-25T00:00:00Z","timestamp":1648166400000},"content-version":"unspecified","delay-in-days":24,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2022,3,3]]},"published-print":{"date-parts":[[2022,3]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>By subsidising access to direct acting antivirals (DAAs) for all people living with hepatitis C (HCV) in 2016, Australia is positioned to eliminate HCV as a public health threat. However, uptake of DAAs has declined over recent years and new initiatives are needed to engage people living with HCV in care. Active follow-up of HCV notifications by the health department to the notifying general practitioner (GP) may increase treatment uptake. In this study, we explore the impact of using hepatitis C notifications systems to engage diagnosing GPs and improve patient access to treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and analysis<\/jats:title>\n                    <jats:p>This study is a randomised controlled trial comparing enhanced case management of HCV notifications with standard of care. The intervention includes phone calls from a department of health (DoH) specialist HCV nurse to notifying GPs and offering HCV management support. The level of support requested by the GP was graded in complexity: level 1: HCV information only; level 2: follow-up testing advice; level 3: prescription support including linkage to specialist clinicians and level 4: direct patient contact. The study population includes all GPs in Tasmania who notified HCV diagnosis to the DoH between September 2020 and December 2021. The primary outcome is proportion of HCV cases who initiate DAAs after 12 weeks of HCV notification to the health department. Secondary outcomes are proportion of HCV notifications that complete HCV RNA testing, treatment workup and treatment completion. Multiple logistic regression modelling will explore factors associated with the primary and secondary outcomes. The sample size required to detect a significant difference for the primary outcome is 85 GPs in each arm with a two-sided alpha of 0.05% and 80% power.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Ethics and dissemination<\/jats:title>\n                    <jats:p>The study was approved by University of Tasmania\u2019s Human Research Ethics Committee (Protocol ID: 18418) on 17 December 2019. Results of the project will be presented in scientific meetings and published in peer-reviewed journals.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration number<\/jats:title>\n                    <jats:p>\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT04510246\">NCT04510246<\/jats:ext-link>\n                      .\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial progression<\/jats:title>\n                    <jats:p>The study commenced recruitment in September 2020 and end of study expected December 2021.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2021-056120","type":"journal-article","created":{"date-parts":[[2022,3,25]],"date-time":"2022-03-25T12:52:22Z","timestamp":1648212742000},"page":"e056120","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":1,"title":["Randomised controlled trial of active case management to link hepatitis C notifications to treatment in Tasmania, Australia: a study protocol"],"prefix":"10.1136","volume":"12","clinical-trial-number":[{"clinical-trial-number":"nct04510246","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1142-6114","authenticated-orcid":false,"given":"Tafireyi","family":"Marukutira","sequence":"first","affiliation":[{"name":"Public Health, Burnet Institute, Melbourne, Victoria, Australia"},{"name":"Department of Epidemiuology, Monash University School of Public Health and Preventive Medicine, Melbourne, Victoria, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karen P","family":"Moore","sequence":"additional","affiliation":[{"name":"Department of Health and Human Services, Hobart, Tasmania, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Margaret","family":"Hellard","sequence":"additional","affiliation":[{"name":"Public Health, Burnet Institute, Melbourne, Victoria, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jacqui","family":"Richmond","sequence":"additional","affiliation":[{"name":"Public Health, Burnet Institute, Melbourne, Victoria, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kate","family":"Turner","sequence":"additional","affiliation":[{"name":"Department of Health and Human Services, Hobart, Tasmania, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A E","family":"Pedrana","sequence":"additional","affiliation":[{"name":"Public Health, Burnet Institute, Melbourne, Victoria, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shannon","family":"Melody","sequence":"additional","affiliation":[{"name":"Department of Health and Human Services, Hobart, Tasmania, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fay H","family":"Johnston","sequence":"additional","affiliation":[{"name":"Department of Health and Human Services, Hobart, Tasmania, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Louise","family":"Owen","sequence":"additional","affiliation":[{"name":"Department of Health and Human Services, Hobart, Tasmania, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wijnand","family":"Van Den Boom","sequence":"additional","affiliation":[{"name":"Public Health, Burnet Institute, Melbourne, Victoria, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N","family":"Scott","sequence":"additional","affiliation":[{"name":"Public Health, Burnet Institute, Melbourne, Victoria, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander","family":"Thompson","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, St Vincent\u2019s Hospital Melbourne Pvt Ltd, Fitzroy, Victoria, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Iser","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, St Vincent\u2019s Hospital Melbourne Pvt Ltd, Fitzroy, Victoria, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tim","family":"Spelman","sequence":"additional","affiliation":[{"name":"Public Health, Burnet Institute, Melbourne, Victoria, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark","family":"Veitch","sequence":"additional","affiliation":[{"name":"Department of Health and Human Services, Hobart, Tasmania, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark A","family":"Stoov\u00e9","sequence":"additional","affiliation":[{"name":"Public Health, Burnet Institute, Melbourne, Victoria, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph","family":"Doyle","sequence":"additional","affiliation":[{"name":"Public Health, Burnet Institute, Melbourne, Victoria, Australia"},{"name":"Department of Infectious Diseases, Alfred Hospital, Melbourne, Victoria, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2022,3,25]]},"reference":[{"key":"2025121222251507000_12.3.e056120.1","unstructured":"World Health Organization . Global hepatitis report 2017. Geneva: World Health Organization, 2017."},{"key":"2025121222251507000_12.3.e056120.2","unstructured":"Kirby Institute . HIV, viral hepatitis and sexually transmissible infections in Australia: annual surveillance report 2018. Sydney: Kirby Institute, 2018."},{"key":"2025121222251507000_12.3.e056120.3","unstructured":"Hepatitis C Virus Infection Consensus Statement Working Group . Australian recommendations for the management of hepatitis C virus infection: a consensus statement. Melbourne: Gastroengerological Society of Australia, 2018."},{"key":"2025121222251507000_12.3.e056120.4","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1080\/17512433.2017.1383894","article-title":"Pathways to the elimination of hepatitis C: prioritising access for all","volume":"10","author":"Pedrana","year":"2017","journal-title":"Expert Rev Clin Pharmacol"},{"key":"2025121222251507000_12.3.e056120.5","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2017.07.006"},{"key":"2025121222251507000_12.3.e056120.6","unstructured":"The Kirby Institute . Monitoring hepatitis C treatment uptake in Australia. Sydney: Kirby Institute, 2018."},{"key":"2025121222251507000_12.3.e056120.7","doi-asserted-by":"crossref","first-page":"365","DOI":"10.5694\/mja2.50544","article-title":"Australia needs to increase testing to achieve hepatitis C elimination","volume":"212","author":"Scott","year":"2020","journal-title":"Med J Aust"},{"key":"2025121222251507000_12.3.e056120.8","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0207226","article-title":"Beyond interferon side effects: what residual barriers exist to DAA hepatitis C treatment for people who inject drugs?","volume":"13","author":"Madden","year":"2018","journal-title":"PLoS One"},{"key":"2025121222251507000_12.3.e056120.9","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.drugalcdep.2018.06.013","article-title":"'Hep C's like the common cold': understanding barriers along the HCV care continuum among young people who inject drugs","volume":"190","author":"Skeer","year":"2018","journal-title":"Drug Alcohol Depend"},{"key":"2025121222251507000_12.3.e056120.10","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/S2055-6640(20)30254-5","article-title":"Implementation of hepatitis C cure in Australia: one year on","volume":"4","author":"Richmond","year":"2018","journal-title":"J Virus Erad"},{"key":"2025121222251507000_12.3.e056120.11","unstructured":"The Director of Public Health . Guidelines for Notifying Diseases and Food Contaminants. In: Public health services TG, department of health and human services. Tasmania: Tasmanian Government, 2016."},{"key":"2025121222251507000_12.3.e056120.12","unstructured":"Communicable Disease Network Australia . Hepatitis C (unspecified) case definition Canberra: Australian government department of health, 2004. Available: http:\/\/www.health.gov.au\/internet\/main\/publishing.nsf\/Content\/cda-surveil-nndss-casedefs-cd_hepcun.htm [Accessed 20 Feb 2019]."},{"key":"2025121222251507000_12.3.e056120.13","doi-asserted-by":"publisher","DOI":"10.1111\/add.14569"},{"key":"2025121222251507000_12.3.e056120.14","doi-asserted-by":"crossref","first-page":"2893","DOI":"10.1111\/add.15459","article-title":"Reduction in the population prevalence of hepatitis C virus viraemia among people who inject drugs associated with scale-up of direct-acting anti-viral therapy in community drug services: real-world data","volume":"116","author":"Palmateer","year":"2021","journal-title":"Addiction"},{"key":"2025121222251507000_12.3.e056120.15","doi-asserted-by":"crossref","DOI":"10.1016\/S0168-8278(20)32037-7","article-title":"A nurse led hepatitis C model of care in primary care and community services in Melbourne, Australia","volume":"73","author":"Harney","year":"2020","journal-title":"J Hepatol"},{"key":"2025121222251507000_12.3.e056120.16","doi-asserted-by":"crossref","unstructured":"O'Brien E , Whelan M , Lama T . Public health unit notifications of hepatitis C and their follow-up in South western Sydney, Australia. Public Health Research & Practice, 2020.","DOI":"10.17061\/phrp30342010"},{"key":"2025121222251507000_12.3.e056120.17","doi-asserted-by":"publisher","DOI":"10.1136\/bmjgast-2020-000396"},{"key":"2025121222251507000_12.3.e056120.18","unstructured":"Tasmanian Government Economic Analysis Unit . Population (ABS cat no 3101.0). Hobart: Department of Treasury and Finance, Tasmanian Government, 2018."},{"key":"2025121222251507000_12.3.e056120.19","unstructured":"Communicable Disease Network Australia . Hepatitis C (newly acquired) case definition Canberra: Australian government department of health, 2015. Available: http:\/\/www.health.gov.au\/internet\/main\/publishing.nsf\/Content\/cda-surveil-nndss-casedefs-cd_hepcnew.htm [Accessed 20 Feb 2019]."},{"key":"2025121222251507000_12.3.e056120.20","unstructured":"Communicable Diseases Network Australia . Australian National notifiable diseases and case definitions: CDNA, 2004. Available: https:\/\/www1.health.gov.au\/internet\/main\/publishing.nsf\/Content\/cdna-casedefinitions.htm"},{"key":"2025121222251507000_12.3.e056120.21","doi-asserted-by":"publisher","DOI":"10.1111\/apt.15210"},{"key":"2025121222251507000_12.3.e056120.22","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.drugpo.2017.05.022","article-title":"Estimating the cascade of hepatitis C testing, care and treatment among people who inject drugs in Australia","volume":"47","author":"Iversen","year":"2017","journal-title":"Int J Drug Policy"},{"key":"2025121222251507000_12.3.e056120.23","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0142770"},{"key":"2025121222251507000_12.3.e056120.24","unstructured":"Burnet Institute and Kirby Institute . Australia\u2019s progress towards hepatitis C elimination - Annual Report 2020. Melbourne: Burnet Institute, 2020."},{"key":"2025121222251507000_12.3.e056120.25","doi-asserted-by":"crossref","first-page":"S817","DOI":"10.1016\/S0168-8278(16)01598-1","article-title":"Feasibilty of recruiting people who inject drugs into a nurse-led model of care trial: the TAP study","volume":"62","author":"Von Bibra","year":"2016","journal-title":"J Hepatol"},{"key":"2025121222251507000_12.3.e056120.26","doi-asserted-by":"crossref","DOI":"10.1016\/S0618-8278(19)30643-7","article-title":"THU-395-Hepatitis C elimination by enhancing care and treatment among HIV co-infected individuals (the co-EC study): real world evidence of decreasing HCV incidence and prevalence","volume":"70","author":"Doyle","year":"2019","journal-title":"J Hepatol"},{"key":"2025121222251507000_12.3.e056120.27","doi-asserted-by":"publisher","DOI":"10.1111\/jgh.13223"},{"key":"2025121222251507000_12.3.e056120.28","doi-asserted-by":"publisher","DOI":"10.1002\/hep.24656"},{"key":"2025121222251507000_12.3.e056120.29","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2016-311504"},{"key":"2025121222251507000_12.3.e056120.30","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2015.07.004"},{"key":"2025121222251507000_12.3.e056120.31","unstructured":"International Committee of Medical Journal Editors . Defining the role of authors and contributors, 2019. Available: http:\/\/www.icmje.org\/recommendations\/browse\/roles-and-responsibilities\/defining-the-role-of-authors-and-contributors.html [Accessed 14th Feb 2019]."},{"key":"2025121222251507000_12.3.e056120.32","doi-asserted-by":"crossref","first-page":"103280","DOI":"10.1016\/j.drugpo.2021.103280","article-title":"\"It's time!\": A qualitative exploration of the acceptability of hepatitis C notification systems to help eliminate hepatitis C","volume":"97","author":"Walker","year":"2021","journal-title":"Int J Drug Policy"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2021-056120","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,13]],"date-time":"2025-12-13T06:25:26Z","timestamp":1765607126000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2021-056120"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3]]},"references-count":32,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2022,3,25]]},"published-print":{"date-parts":[[2022,3]]}},"alternative-id":["10.1136\/bmjopen-2021-056120"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2021-056120","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"type":"print","value":"2044-6055"},{"type":"electronic","value":"2044-6055"}],"subject":[],"published":{"date-parts":[[2022,3]]}}}